Clinical Trial Finder

Inclusion Criteria:

• - Provide written informed consent prior to initiation of any study-specific procedures.

• - Metastatic or advanced stage solid tumor.

• - Known BRAF Class I, Class II, or Class III alteration or melanoma with an NRAS mutation as confirmed by previous genomic analysis of tumor tissue or ctDNA.

• - Measurable (Part A and B) or evaluable (Part A only) disease by RECIST v1.1.

• - ECOG performance status 0-1.

• - Adequate organ function, as measured by laboratory values (criteria listed in protocol).

• - Able to swallow, retain, and absorb oral medications.

Exclusion Criteria:

• - Known participants who have received local therapy with either surgery and/or radiation therapy (participants with asymptomatic untreated brain metastasis may be eligible if met with certain criteria) - In Part B Dose Expansion, previous treatment with any approved or in-development small molecule BRAF-, MEK-, or MAPK-directed inhibitor therapy.

• - GI tract disease causing an inability to take oral medication, malabsorption syndrome, requirement for intravenous alimentation, or uncontrolled inflammatory GI disease.

• - Active, uncontrolled bacterial, fungal, or viral infection.

• - Participant with a positive test result for SARS-CoV2 infection, is known to have asymptomatic infection or is suspected of having SARS-CoV2, is excluded.

• - Women who are lactating or breastfeeding, or pregnant.

• - Participants with any other active treated malignancy within 3 years prior to enrollment.

This is a two-part, open-label, multi-center, dose escalation and dose expansion study in participants with BRAF mutation-positive and/or NRAS mutation-positive tumors designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of KIN-2787, a RAF small molecule kinase inhibitor, to determine a recommended Phase 2 dose (RP2D) of KIN-2787, and to assess the objective response to KIN-2787 therapy alone and in combination with binimetinib, a mitogen-activated protein kinase (MEK) inhibitor. The dose expansion phase (Part B) will assess the safety and efficacy of KIN-2787 at the recommended dose and schedule in patients with cancers that contain BRAF Class I, II or III mutations, including lung cancer, melanoma, and other selected solid tumors.

Arms

Interventions